These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27684943)

  • 1. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.
    Tsivgoulis G; Katsanos AH; Mavridis D; Grigoriadis N; Dardiotis E; Heliopoulos I; Papathanasopoulos P; Karapanayiotides T; Kilidireas C; Hadjigeorgiou GM; Voumvourakis K;
    PLoS One; 2016; 11(9):e0163296. PubMed ID: 27684943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
    Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
    Front Neurol; 2021; 12():699844. PubMed ID: 34497577
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
    Meca-Lallana J; Ayuso T; Martínez-Yelamos S; Durán C; Contreras Martín Y; Herrera Navarro N; Pérez Sempere A; Álvarez-Cermeño JC; Millán Pascual J; Meca-Lallana V; Romero Sevilla R; Ricart J
    Eur Neurol; 2020; 83(1):25-33. PubMed ID: 32187609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab in spinal multiple sclerosis in a daily clinical setting.
    Zecca C; Heldner MR; Kamm CP; Riccitelli GC; Disanto G; Caporro M; Cianfoni A; Pravatà E; Gobbi C
    Expert Opin Biol Ther; 2015 May; 15(5):633-40. PubMed ID: 25840751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu X; Xue T; Wang Z; Chen Z; Zhang X; Zhang W; Wang Z
    Front Pharmacol; 2021; 12():621856. PubMed ID: 34079453
    [No Abstract]   [Full Text] [Related]  

  • 13. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network analysis of randomized controlled trials in multiple sclerosis.
    Zintzaras E; Doxani C; Mprotsis T; Schmid CH; Hadjigeorgiou GM
    Clin Ther; 2012 Apr; 34(4):857-869.e9. PubMed ID: 22444787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.
    Outteryck O; Ongagna JC; Brochet B; Rumbach L; Lebrun-Frenay C; Debouverie M; Zéphir H; Ouallet JC; Berger E; Cohen M; Pittion S; Laplaud D; Wiertlewski S; Cabre P; Pelletier J; Rico A; Defer G; Derache N; Camu W; Thouvenot E; Moreau T; Fromont A; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Casez O; Hautecoeur P; Papeix C; Lubetzki C; Fontaine B; Couturier N; Bohossian N; Clanet M; Vermersch P; de Sèze J; Brassat D; ;
    Eur J Neurol; 2014; 21(1):40-8. PubMed ID: 23895407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.